Literature DB >> 25717220

Annual report on status of cancer in China, 2011.

Wanqing Chen1, Rongshou Zheng1, Hongmei Zeng1, Siwei Zhang1, Jie He1.   

Abstract

OBJECTIVE: The National Central Cancer Registry (NCCR) collected population-based cancer registration data in 2011 from all cancer registries. National cancer incidence and mortality were compiled and cancer incident new cases and cancer deaths were estimated.
METHODS: In 2014, there were 234 cancer registries submitted cancer incidence and deaths occurred in 2011. All datasets were checked and evaluated based on the criteria of data quality from NCCR. Total 177 registries' data were qualified and compiled for cancer statistics in 2011. The pooled data were stratified by area (urban/rural), gender, age group (0, 1-4, 5-9, 10-14…85+) and cancer type. Cancer incident cases and deaths were estimated using age-specific rates and national population in 2011. All incidence and death rates are age-standardized to the 2000 Chinese standard population and Segi's population expressed per 100,000 persons.
RESULTS: All 177 cancer registries (77 in urban and 100 in rural areas) covered 175,310,169 populations (98,341,507 in urban and 76,968,662 in rural areas). The morphology verified cases (MV%) accounting for 70.14% and 2.44% of incident cases were identified through death certifications only (DCO%) with mortality to incidence ratio of 0.63. The estimates of new cancer incident cases and cancer deaths were 3,372,175 and 2,113,048 in 2011, respectively. The incidence rate was 250.28/100,000 (males 277.77/100,000, females 221.37/100,000), and the age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 186.34/100,000 and 182.76/100,000 with the cumulative incidence rate (0-74 years old) of 21.20%. The cancer incidence and ASIRC in urban areas were 261.38/100,000 and 189.89/100,000 compared to 238.60/100,000 and 182.10/100,000 in rural areas, respectively. The cancer mortality was 156.83/100,000 (194.88/100,000 in males and 116.81/100,000 in females), the age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 112.88/100,000 and 111.82/100,000, and the cumulative mortality rate (0-74 years old) was 12.69%. The cancer mortality and ASMRC were 154.37/100,000 and 108.20/100,000 in urban areas, and 159.42/100,000 and 117.97/100,000 in rural areas, respectively. Cancers of lung, female breast, stomach, liver, colon and rectum, esophageal, cervix, uterus, prostate and ovary were the most common cancers, accounting for about 75% of all cancer new cases. Lung cancer, liver cancer, stomach cancer, esophageal cancer, colorectal cancer, female breast cancer, pancreatic cancer, brain tumor, cervical cancer and leukemia were the leading causes of cancer death, accounting for about 80% of all cancer deaths. The cancer incidence, mortality and spectrum showed difference between urban and rural areas, males and females.
CONCLUSIONS: The coverage of cancer registration population had a greater increase than that in the last year. The data quality and representativeness are gradually improved. As the basic work of cancer prevention and control, cancer registry is playing an irreplaceable role. The disease burden of cancer is increasing, and the health department has to take effective measures to contain the increased cancer burden in China.

Entities:  

Keywords:  Cancer registry; China; epidemiology; incidence; mortality

Year:  2015        PMID: 25717220      PMCID: PMC4329176          DOI: 10.3978/j.issn.1000-9604.2015.01.06

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  11 in total

Review 1.  The evolution of the population-based cancer registry.

Authors:  Donald M Parkin
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

2.  Factors associated with smoking cessation among Chinese adults in rural China.

Authors:  Tingzhong Yang; Abu Saleh M Abdullah; Jabed Mustafa; Bin Chen; Xiaozhao Yang; Xiangxian Feng
Journal:  Am J Health Behav       Date:  2009 Mar-Apr

3.  [Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989-2008].

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2014-10

4.  [Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 - 2005].

Authors:  Jian-guo Chen; Si-wei Zhang; Wan-qing Chen
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2010-05

5.  Air pollution and lung cancer risks in China--a meta-analysis.

Authors:  Yu Zhao; Shuxiao Wang; Kristin Aunan; Hans Martin Seip; Jiming Hao
Journal:  Sci Total Environ       Date:  2006-01-10       Impact factor: 7.963

6.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

7.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

8.  [Trend analysis of cancer mortality in China between 1989 and 2008].

Authors:  Hong-mei Zeng; Rong-shou Zheng; Si-wei Zhang; Ping Zhao; Jie He; Wan-qing Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

9.  [Trend analysis and projection of cancer incidence in China between 1989 and 2008].

Authors:  Wan-qing Chen; Rong-shou Zheng; Hong-mei Zeng; Si-wei Zhang; Ping Zhao; Jie He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

10.  Cancer survival in China, 2003-2005: a population-based study.

Authors:  Hongmei Zeng; Rongshou Zheng; Yuming Guo; Siwei Zhang; Xiaonong Zou; Ning Wang; Limei Zhang; Jingao Tang; Jianguo Chen; Kuangrong Wei; Suqin Huang; Jian Wang; Liang Yu; Deli Zhao; Guohui Song; Jianshun Chen; Yongzhou Shen; Xiaoping Yang; Xiaoping Gu; Feng Jin; Qilong Li; Yanhua Li; Hengming Ge; Fengdong Zhu; Jianmei Dong; Guoping Guo; Ming Wu; Lingbin Du; Xibin Sun; Yutong He; Michel P Coleman; Peter Baade; Wanqing Chen; Xue Qin Yu
Journal:  Int J Cancer       Date:  2014-10-03       Impact factor: 7.396

View more
  338 in total

1.  [miR-122-5p inhibits the proliferation of melanoma cells by targeting NOP14].

Authors:  Jingrong Li; Rui Zhao; Ruihua Fang; Jianqin Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

Authors:  Yuankai Shi; Yan Sun; Cuimin Ding; Ziping Wang; Changli Wang; Zheng Wang; Chong Bai; Chunxue Bai; Jifeng Feng; Xiaoqing Liu; Fang Li; Yue Yang; Yongqian Shu; Milu Wu; Jianxing He; Yiping Zhang; Shucai Zhang; Gongyan Chen; Honghe Luo; Rongcheng Luo; Caicun Zhou; Yanbin Zhou; Qingsong Pang; Hong Zhao; Qiong Zhao; Aiqin Gu; Yang Ling; Cheng Huang; Baohui Han; Shunchang Jiao; Hong Jiao
Journal:  Ann Transl Med       Date:  2015-10

Review 3.  China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

Authors:  Yuankai Shi; Yan Sun; Cuimin Ding; Ziping Wang; Changli Wang; Zheng Wang; Chong Bai; Chunxue Bai; Jifeng Feng; Xiaoqing Liu; Fang Li; Yue Yang; Yongqian Shu; Milu Wu; Jianxing He; Yiping Zhang; Shucai Zhang; Gongyan Chen; Honghe Luo; Rongcheng Luo; Caicun Zhou; Yanbin Zhou; Qingsong Pang; Hong Zhao; Qiong Zhao; Aiqin Gu; Yang Ling; Cheng Huang; Baohui Han; Shunchang Jiao; Hong Jiao
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

4.  Role of multi-mode ultrasound in the diagnosis of level 4 BI-RADS breast lesions and Logistic regression model.

Authors:  Xiaoling Leng; Guofu Huang; Lanhui Yao; Fucheng Ma
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription.

Authors:  Qipeng Xie; Caiyi Chen; Haiying Li; Jiheng Xu; Lei Wu; Yuan Yu; Shuwei Ren; Hongyan Li; Xiaohui Hua; Huiying Yan; Dapang Rao; Huxiang Zhang; Honglei Jin; Haishan Huang; Chuanshu Huang
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

6.  The impact of operative approaches on outcomes of middle and lower third esophageal squamous cell carcinoma.

Authors:  Ju-Wei Mu; Shu-Geng Gao; Qi Xue; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yu-Shun Gao; Jin-Feng Huang; Jie He
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

7.  Expenditure of hospital care on cancer in China, from 2011 to 2015.

Authors:  Yue Cai; Ming Xue; Wanqing Chen; Maogui Hu; Zhiwen Miao; Lan Lan; Rongshou Zheng; Qun Meng
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

8.  Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Authors:  Yuan-Yuan Lei; Jin-Ji Yang; Wen-Zhao Zhong; Hua-Jun Chen; Hong-Hong Yan; Jie-Fei Han; Lu-Lu Yang; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

9.  NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.

Authors:  Jinhuai Hu; Yong Huang; Yuanhua Wu; Fengjun Liu; Dong Sun; Kexin Wang; Hui Qu
Journal:  Tumour Biol       Date:  2016-09-23

10.  Using gastric juice lncRNA-ABHD11-AS1 as a novel type of biomarker in the screening of gastric cancer.

Authors:  Yunben Yang; Yongfu Shao; Mengying Zhu; Qier Li; Fang Yang; Xuwen Lu; Chunjing Xu; Bingxiu Xiao; Yanke Sun; Junming Guo
Journal:  Tumour Biol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.